EUVIMEDEUVIMED entdecken
Crossref

Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care

Li Zhang, Lei Zhang, Ping Li, Chenwei Liu, Qiwen Zheng, Yan Wang

The Journal of Clinical Pharmacology · 2023

DOI: 10.1002/jcph.2210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Li Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Venous Thromboembolism. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate whether early antifactor Xa (anti‐Xa) achieved the target range when venous thromboembolism (VTE) was treated with low‐molecular‐weight heparin (LMWH), based on body weight and renal function in patients treated in intensive care units (ICUs). Anti‐Xa levels in patients treated with LMWH for VTE in ICU and medical wards between January 1, 2021, and June 30, 2022, were retrospectively assessed. The demographics, laboratory parameters, and early anti‐Xa peak levels of patients were collected. All patients were followed up for 3 months to collect VTE recurrence/bleeding events. Univariate and multivariate linear regression analyses were used to identify the factors affecting anti‐Xa levels. A total of 108 patients were enrolled in this study, including 70 patients in ICU and 38 patients on medical wards. The early anti‐Xa level (0.36 vs 0.61 IU/mL, P < .001) and target achievement rate (21.4% vs 39.5%, P = .015) of patients in ICU were lower than those in medical wards. Multivariate linear regression showed that only antithrombin (AT) significantly affected anti‐Xa levels in patients in ICU ( β = 0.008, 95%CI 0.005 to 0.011, P < .001). There was no significant difference in VTE recurrence events (11.8% vs 7.5%, P = .628) and bleeding events (29.4% vs 17.0%, P = .304) between the early anti‐Xa within‐target group and the early anti‐Xa below‐target group. Low anti‐Xa peak levels are common in patients in ICU. AT activity should be monitored when using LMWH in critically ill patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heparin, Low-Molecular-WeightVenous ThromboembolismHumansRetrospective StudiesFactor Xa InhibitorsAnticoagulantsCritical CareHemorrhageHeparin

Stichwörter der Autor:innen

antifactor Xaantithrombinintensive care unitlow-molecular-weight heparinvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightFactor Xa InhibitorsAnticoagulantsHeparin

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Emergency Intensive Care Unit, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Förderung

  • National Natural Science Foundation of China
  • Chinese Pharmaceutical Association

Zitieren

APA

Zhang, L., Zhang, L., Li, P., Liu, C., Zheng, Q., & Wang, Y. (2023). Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2210

Vancouver

Zhang L, Zhang L, Li P, Liu C, Zheng Q, Wang Y. Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2210

BibTeX
@article{Zhang2023,
  author = {Zhang, Li and Zhang, Lei and Li, Ping and Liu, Chenwei and Zheng, Qiwen and Wang, Yan},
  title = {Low Early Antifactor Xa Target Achievement Rate of Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients in Intensive Care},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1002/jcph.2210}
}
Kostenlos starten →